Cancer vaccine therapy using dendritic cells and cancer antigen peptide against patients with advanced gastrointerstinal cancer

Fumiaki Tanaka, Mitsuhiko Ohta, Naotsugu Haraguchi, Koshi Mimori, Atsushi Sasaki, Tohru Utsunomiya, Hiroshi Inoue, Masaki Mori

Research output: Contribution to journalReview article

Abstract

Background: We conducted a clinical study using dendritic cells (DCs) and MAGE peptides for patients with advanced gastrointestinal cancer. The patients had already been treated with standard therapy such as surgery, chemotherapy and radiation therapy. They also had a measurable disease as revealed by CT. Considering these situations, the patients who joined the study had a poor systemic condition. Here we report the results of our cancer vaccine therapy, and consider the method for evaluating the efficacy of cancer vaccine. Patients and results: We performed vaccine therapy on 24 patients; 6 with esophageal cancer, 10 with gastric cancer, 6 with colorectal cancer, 1 with pancreatic cancer, and 1 with gall bladder cancer. No patients showed more than grade 3 adverse events in relation to the vaccine therapy. Eleven of 24 patients showed decrease of tumor marker. No patients exhibited effective results that were based on RECIST (PR and CR). Three evidenced MR, 1 long NC, and 1 a combination of MR and PD. The other 10 patients showed PD. Conclusion: No patients showed PR or CR by this vaccine therapy alone. The kinetics of tumor marker, CTL response, DTH, and Th1/Th2 balance seems to be related with clinical status to some degree, however none were critical. Based on the evaluation by RECIST, this vaccine therapy was considered "not effective". We suggest that a new evaluation method is required for cancer vaccine therapy that may contribute to improvement of PS of patients, and tumor dormancy therapy.

Original languageEnglish
Pages (from-to)197-200
Number of pages4
JournalBiotherapy
Volume20
Issue number2
Publication statusPublished - Mar 1 2006

Fingerprint

Active Immunotherapy
Cancer Vaccines
Dendritic Cells
Antigens
Peptides
Neoplasms
Tumor Biomarkers
Th1-Th2 Balance
Gallbladder Neoplasms
Gastrointestinal Neoplasms
Esophageal Neoplasms
Pancreatic Neoplasms
Stomach Neoplasms
Colorectal Neoplasms
Radiotherapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Cancer vaccine therapy using dendritic cells and cancer antigen peptide against patients with advanced gastrointerstinal cancer. / Tanaka, Fumiaki; Ohta, Mitsuhiko; Haraguchi, Naotsugu; Mimori, Koshi; Sasaki, Atsushi; Utsunomiya, Tohru; Inoue, Hiroshi; Mori, Masaki.

In: Biotherapy, Vol. 20, No. 2, 01.03.2006, p. 197-200.

Research output: Contribution to journalReview article

Tanaka, F, Ohta, M, Haraguchi, N, Mimori, K, Sasaki, A, Utsunomiya, T, Inoue, H & Mori, M 2006, 'Cancer vaccine therapy using dendritic cells and cancer antigen peptide against patients with advanced gastrointerstinal cancer', Biotherapy, vol. 20, no. 2, pp. 197-200.
Tanaka, Fumiaki ; Ohta, Mitsuhiko ; Haraguchi, Naotsugu ; Mimori, Koshi ; Sasaki, Atsushi ; Utsunomiya, Tohru ; Inoue, Hiroshi ; Mori, Masaki. / Cancer vaccine therapy using dendritic cells and cancer antigen peptide against patients with advanced gastrointerstinal cancer. In: Biotherapy. 2006 ; Vol. 20, No. 2. pp. 197-200.
@article{9c9392acda7946eba9159720907a321c,
title = "Cancer vaccine therapy using dendritic cells and cancer antigen peptide against patients with advanced gastrointerstinal cancer",
abstract = "Background: We conducted a clinical study using dendritic cells (DCs) and MAGE peptides for patients with advanced gastrointestinal cancer. The patients had already been treated with standard therapy such as surgery, chemotherapy and radiation therapy. They also had a measurable disease as revealed by CT. Considering these situations, the patients who joined the study had a poor systemic condition. Here we report the results of our cancer vaccine therapy, and consider the method for evaluating the efficacy of cancer vaccine. Patients and results: We performed vaccine therapy on 24 patients; 6 with esophageal cancer, 10 with gastric cancer, 6 with colorectal cancer, 1 with pancreatic cancer, and 1 with gall bladder cancer. No patients showed more than grade 3 adverse events in relation to the vaccine therapy. Eleven of 24 patients showed decrease of tumor marker. No patients exhibited effective results that were based on RECIST (PR and CR). Three evidenced MR, 1 long NC, and 1 a combination of MR and PD. The other 10 patients showed PD. Conclusion: No patients showed PR or CR by this vaccine therapy alone. The kinetics of tumor marker, CTL response, DTH, and Th1/Th2 balance seems to be related with clinical status to some degree, however none were critical. Based on the evaluation by RECIST, this vaccine therapy was considered {"}not effective{"}. We suggest that a new evaluation method is required for cancer vaccine therapy that may contribute to improvement of PS of patients, and tumor dormancy therapy.",
author = "Fumiaki Tanaka and Mitsuhiko Ohta and Naotsugu Haraguchi and Koshi Mimori and Atsushi Sasaki and Tohru Utsunomiya and Hiroshi Inoue and Masaki Mori",
year = "2006",
month = "3",
day = "1",
language = "English",
volume = "20",
pages = "197--200",
journal = "Biotherapy",
issn = "0914-2223",
number = "2",

}

TY - JOUR

T1 - Cancer vaccine therapy using dendritic cells and cancer antigen peptide against patients with advanced gastrointerstinal cancer

AU - Tanaka, Fumiaki

AU - Ohta, Mitsuhiko

AU - Haraguchi, Naotsugu

AU - Mimori, Koshi

AU - Sasaki, Atsushi

AU - Utsunomiya, Tohru

AU - Inoue, Hiroshi

AU - Mori, Masaki

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Background: We conducted a clinical study using dendritic cells (DCs) and MAGE peptides for patients with advanced gastrointestinal cancer. The patients had already been treated with standard therapy such as surgery, chemotherapy and radiation therapy. They also had a measurable disease as revealed by CT. Considering these situations, the patients who joined the study had a poor systemic condition. Here we report the results of our cancer vaccine therapy, and consider the method for evaluating the efficacy of cancer vaccine. Patients and results: We performed vaccine therapy on 24 patients; 6 with esophageal cancer, 10 with gastric cancer, 6 with colorectal cancer, 1 with pancreatic cancer, and 1 with gall bladder cancer. No patients showed more than grade 3 adverse events in relation to the vaccine therapy. Eleven of 24 patients showed decrease of tumor marker. No patients exhibited effective results that were based on RECIST (PR and CR). Three evidenced MR, 1 long NC, and 1 a combination of MR and PD. The other 10 patients showed PD. Conclusion: No patients showed PR or CR by this vaccine therapy alone. The kinetics of tumor marker, CTL response, DTH, and Th1/Th2 balance seems to be related with clinical status to some degree, however none were critical. Based on the evaluation by RECIST, this vaccine therapy was considered "not effective". We suggest that a new evaluation method is required for cancer vaccine therapy that may contribute to improvement of PS of patients, and tumor dormancy therapy.

AB - Background: We conducted a clinical study using dendritic cells (DCs) and MAGE peptides for patients with advanced gastrointestinal cancer. The patients had already been treated with standard therapy such as surgery, chemotherapy and radiation therapy. They also had a measurable disease as revealed by CT. Considering these situations, the patients who joined the study had a poor systemic condition. Here we report the results of our cancer vaccine therapy, and consider the method for evaluating the efficacy of cancer vaccine. Patients and results: We performed vaccine therapy on 24 patients; 6 with esophageal cancer, 10 with gastric cancer, 6 with colorectal cancer, 1 with pancreatic cancer, and 1 with gall bladder cancer. No patients showed more than grade 3 adverse events in relation to the vaccine therapy. Eleven of 24 patients showed decrease of tumor marker. No patients exhibited effective results that were based on RECIST (PR and CR). Three evidenced MR, 1 long NC, and 1 a combination of MR and PD. The other 10 patients showed PD. Conclusion: No patients showed PR or CR by this vaccine therapy alone. The kinetics of tumor marker, CTL response, DTH, and Th1/Th2 balance seems to be related with clinical status to some degree, however none were critical. Based on the evaluation by RECIST, this vaccine therapy was considered "not effective". We suggest that a new evaluation method is required for cancer vaccine therapy that may contribute to improvement of PS of patients, and tumor dormancy therapy.

UR - http://www.scopus.com/inward/record.url?scp=33646108337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646108337&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:33646108337

VL - 20

SP - 197

EP - 200

JO - Biotherapy

JF - Biotherapy

SN - 0914-2223

IS - 2

ER -